Literature DB >> 29850928

Reply to the letter.

Hajira Ilyas1, N George Mikhaeel2, Joel T Dunn3, Fareen Rahman2, Henrik Møller4, Daniel Smith2, Sally F Barrington3.   

Abstract

Year:  2018        PMID： 29850928     DOI： 10.1007/s00259-018-4050-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.

Authors:  Andrea Gallamini; Lale Kostakoglu
Journal:  J Nucl Med       Date:  2016-11-10       Impact factor: 10.057

2.  An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

Authors:  Emmanuel Itti; Michel Meignan; Alina Berriolo-Riedinger; Alberto Biggi; Amanda F Cashen; Pierre Véra; Hervé Tilly; Barry A Siegel; Andrea Gallamini; René-Olivier Casasnovas; Corinne Haioun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236

3.  High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.

Authors:  Moo-Kon Song; Deok-Hwan Yang; Gyeong-Won Lee; Sung-Nam Lim; Seunghyeon Shin; Kyoung June Pak; Seong Young Kwon; Hye Kyung Shim; Bong-Hoi Choi; In-Suk Kim; Dong-Hoon Shin; Seong-Geun Kim; So-Yeon Oh
Journal:  Leuk Res       Date:  2016-01-24       Impact factor: 3.156

4.  International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

Authors:  Alberto Biggi; Andrea Gallamini; Stephane Chauvie; Martin Hutchings; Lale Kostakoglu; Michele Gregianin; Michel Meignan; Bogdan Malkowski; Michael S Hofman; Sally F Barrington
Journal:  J Nucl Med       Date:  2013-03-20       Impact factor: 10.057

5.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673

6.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Authors:  Ronald Boellaard; Roberto Delgado-Bolton; Wim J G Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J Verzijlbergen; Sally F Barrington; Lucy C Pike; Wolfgang A Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J Donohoe; Scott Holbrook; Michael M Graham; Giorgio Testanera; Otto S Hoekstra; Josee Zijlstra; Eric Visser; Corneline J Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; Jörg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-02       Impact factor: 9.236

7.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.

Authors:  Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Møller; Daniel Smith; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

8.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Authors:  Sally F Barrington; Amy A Kirkwood; Antonella Franceschetto; Michael J Fulham; Thomas H Roberts; Helén Almquist; Eva Brun; Karin Hjorthaug; Zaid N Viney; Lucy C Pike; Massimo Federico; Stefano Luminari; John Radford; Judith Trotman; Alexander Fosså; Leanne Berkahn; Daniel Molin; Francesco D'Amore; Donald A Sinclair; Paul Smith; Michael J O'Doherty; Lindsey Stevens; Peter W Johnson
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113
  8 in total
  1 in total

1.  Could we avoid computing TMTV of DLBCL patients in routine practice?

Authors:  Eric Laffon; Roger Marthan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.